Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$19.0 million.

  • Rxo's Gains from Investment Securities rose 8173.08% to -$19.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.0 million, marking a year-over-year increase of 37142.86%. This contributed to the annual value of $19.0 million for FY2025, which is 37142.86% up from last year.
  • Per Rxo's latest filing, its Gains from Investment Securities stood at -$19.0 million for Q4 2025, which was up 8173.08% from $16.0 million recorded in Q3 2025.
  • Over the past 5 years, Rxo's Gains from Investment Securities peaked at $48.0 million during Q3 2024, and registered a low of -$104.0 million during Q4 2024.
  • Its 5-year average for Gains from Investment Securities is -$1.1 million, with a median of $16.0 million in 2025.
  • As far as peak fluctuations go, Rxo's Gains from Investment Securities surged by 30000.0% in 2023, and later tumbled by 12608.7% in 2024.
  • Over the past 5 years, Rxo's Gains from Investment Securities (Quarter) stood at -$38.0 million in 2021, then tumbled by 36.84% to -$52.0 million in 2022, then grew by 11.54% to -$46.0 million in 2023, then tumbled by 126.09% to -$104.0 million in 2024, then surged by 81.73% to -$19.0 million in 2025.
  • Its last three reported values are -$19.0 million in Q4 2025, $16.0 million for Q3 2025, and $5.0 million during Q2 2025.